← Leaderboards
Matthew Stephen Block
Mayo Clinic Jacksonville
$2,473,112
Attributed
$5,327,929
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,327,929 · 4
By mechanism
R01$4,341,678 · 2
R41$547,802 · 1
P50$438,449 · 1
Top collaborators
- Jamie N Bakkum-Gamez5 shared
- Kah-Whye Peng5 shared
- Keith L Knutson3 shared
- Chun Wang2 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Keith L Knutson$7,418,327
- Mark E Sherman$5,733,205
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorResponseSafetyRecurrenceNeoantigensDisease RemissionImmunityObjective Response RatePhase I Clinical TrialsT Cell ResponseRecurrent DiseaseImmune ResponseCessation Of LifeSuccessGrantPreclinical StudyVaccine DevelopmentMalignant NeoplasmsAntigensNormal Tissue MorphologyMouse ModelT-LymphocyteAntibodiesPre-Clinical
Grant awards (12)
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer$639,109
R01 · FY2025 · CA
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer$607,154
R01 · FY2024 · CA
Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence$202,553
P50 · FY2024 · CA · contact PI
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer$634,953
R01 · FY2023 · CA
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform$399,979
R41 · FY2023 · CA
Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence$235,896
P50 · FY2023 · CA · contact PI
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform$147,823
R41 · FY2023 · CA
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$373,073
R01 · FY2021 · CA
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$543,708
R01 · FY2020 · CA
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$527,396
R01 · FY2019 · CA
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$543,708
R01 · FY2018 · CA
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$472,577
R01 · FY2017 · CA